Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

Keyphrases

• Neuroblastoma 100%
• MYCN Amplification 100%
• Chromosome 11q 100%
• Checkpoint Kinase 1 (CHK1) 100%
• Synthetic Lethality 100%
• Loss Amplification 100%
• Tumor 20%
• Therapeutic Vulnerabilities 20%
• Isogenic 20%
• Clinical High Risk 20%
• Overall Survival Rate 20%
• Drug Combination 20%
• Putative Drug Targets 20%
• Therapeutic Approaches 20%
• Chromosomal Aberrations 20%
• Novel Therapeutic Targets 20%
• Patient Outcomes 20%
• Extracranial Solid Tumors 20%
• DNA Damage Repair 20%
• Preclinical Development 20%
• High-throughput Screening 20%
• Multimodal Therapeutics 20%
• Stress Response Pathway 20%
• Potential Power 20%
• System Throughput 20%
• Replication Stress Response 20%

Medicine and Dentistry

• Ganglioneuroblastoma 100%
• Checkpoint Kinase 1 100%
• Lethality 100%
• Chromosome 11q 100%
• Neoplasm 20%
• Solid Malignant Neoplasm 20%
• Biological Marker 20%
• Survival Rate 20%
• Overall Survival 20%
• DNA Repair 20%
• Chromosome Aberration 20%
• High Throughput Screening 20%

Biochemistry, Genetics and Molecular Biology

• Chromosome 11q 100%
• Kinase 100%
• Phosphotransferase 100%
• Overall Survival 33%
• DNA Repair 33%
• Preclinical Study 33%
• Survival Rate 33%
• Chromosomal Aberration 33%
• High Throughput Screening 33%